CTT Pharma signs LOI for U.S. nicotine product clinical trials
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
CTT Pharma Signs LOI for Clinical Trials and Testing of Nicotine Products
June 22, 2026 6:01 AM EDTTAMPA, FL / ACCESS Newswire / June 22, 2026 / CTT Pharmaceutical Holdings, Inc. (OTCQB: CTTH) has signed an LOI with a testing company in the United States to conduct clinical trials and testing for several potential nicotine products for CTT Pharma. A partnership with this company would allow CTT the ability to independently go to market in the United States utilizing our patented... More
